# A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

> **NCT04200352** · PHASE3 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Cerebral Palsy, Dyskinetic

## Interventions

- **DRUG:** TEV-50717

## Key facts

- **NCT ID:** NCT04200352
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-04
- **Primary completion:** 2023-02-14
- **Final completion:** 2023-02-14
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Failure of TV50717-CNS-30080 (parent study) to meet the primary efficacy endpoint
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04200352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04200352, "A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04200352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*